List of Excipients in Branded Drug JYLAMVO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SHORLA ONCOLOGY INC	JYLAMVO	methotrexate	81927-204	CITRIC ACID MONOHYDRATE	2035-10-28
SHORLA ONCOLOGY INC	JYLAMVO	methotrexate	81927-204	ETHYLPARABEN	2035-10-28
SHORLA ONCOLOGY INC	JYLAMVO	methotrexate	81927-204	GLYCERIN	2035-10-28

Jylamvo Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 8, 2026

Jylamvo is a 2 mg/mL oral solution of methotrexate for once-weekly administration in rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, and acute lymphoblastic leukemia. Its commercial differentiation is based less on the active ingredient, which is generic and injectable, than on oral liquid delivery, dosing accessibility, stability, and risk controls for a high-alert medicine.

The formulation uses macrogol 400, sucralose, sodium benzoate, citric acid monohydrate, sodium citrate, raspberry flavor, and purified water. The principal commercial opportunity is to develop differentiated methotrexate liquids that improve pediatric acceptability, dose accuracy, adherence, storage, or medication-error prevention without compromising chemical stability or regulatory comparability. [1]

What excipients are used in Jylamvo?

Jylamvo contains a relatively conventional aqueous oral-solution excipient system.

Excipient	Primary formulation role	Commercial relevance
Macrogol 400	Co-solvent, viscosity modifier, solubilization aid	Supports a clear, homogeneous liquid and may improve mouthfeel
Sucralose	High-intensity sweetener	Reduces methotrexate bitterness and supports pediatric use
Sodium benzoate	Preservative	Helps control microbial growth in a multidose container
Citric acid monohydrate	Acidifying agent and buffer component	Controls pH and supports chemical stability
Sodium citrate	Buffer component	Helps maintain target pH during shelf life
Raspberry flavor	Taste-masking agent	Supports patient acceptance, especially in children
Purified water	Vehicle	Main liquid phase

The product is supplied as a 2 mg/mL oral solution. The dose volume therefore varies substantially by indication and patient body surface area. A 10 mg dose requires 5 mL, while a 50 mg dose requires 25 mL. That dosing profile makes the oral syringe, graduated delivery system, labeling, and weekly-use instructions commercially important parts of the product rather than secondary packaging details. [1]

Why does macrogol 400 matter?

Macrogol 400, also known as polyethylene glycol 400, is commonly used as a pharmaceutical solvent and co-solvent. In Jylamvo, it can support methotrexate solubilization and contribute to a uniform liquid dose.

Its strategic value is limited as a standalone differentiator because it is widely used in oral liquid formulations. A competitor would usually need to demonstrate a measurable benefit, such as improved stability, reduced precipitation, better taste, or lower viscosity, before replacing it.

Potential development issues include:

• viscosity changes across temperature ranges;
• interaction with container-closure materials;
• altered preservative performance;
• gastrointestinal tolerability at higher concentrations; and
• differences in dose delivery through oral syringes.

Why are citric acid and sodium citrate combined?

Citric acid and sodium citrate form a buffer system. Methotrexate has pH-dependent solubility and stability characteristics, so pH control is central to maintaining a clear and consistent oral solution.

A competing formulation cannot assume that a different pH will be clinically neutral. Changes may affect:

• methotrexate degradation;
• precipitation during storage;
• preservative efficacy;
• flavor intensity;
• taste perception; and
• compatibility with plastic bottles and syringes.

The buffer system is therefore a potential formulation design-around area, but it is also a technical barrier. A new buffer may create a new patent position only if it produces a documented advantage over the established formulation.

What formulation patents protect Jylamvo?

Public product information confirms the composition and dosage form, but the cited regulatory documents do not establish a complete, current patent family for Jylamvo or provide a verified list of formulation patent numbers and expiration dates. Jylamvo is not an FDA-approved product with an established U.S. Orange Book listing in the cited FDA materials. [1][2]

The likely intellectual-property value is concentrated in formulation and use claims rather than methotrexate compound claims. Relevant claim categories may include:

Claim category	Potential scope	Competitive importance
Oral methotrexate solution	Methotrexate concentration, solvent, buffer, sweetener, preservative, and flavor	Can delay direct formulation copying
Stable liquid formulation	Shelf-life performance and resistance to precipitation or degradation	Supports regulatory and commercial differentiation
Multidose packaging	Bottle, closure, syringe, tamper evidence, and dose-control system	May protect the marketed presentation
Pediatric administration	Oral dosing for juvenile patients or specific body-surface-area regimens	More likely to overlap with method-of-use protection
Medication-error reduction	Weekly dosing instructions, packaging, or delivery controls	Can support product differentiation but may be difficult to patent broadly

A freedom-to-operate review should separate three issues: patent ownership, patent validity, and enforceable territorial scope. A formulation patent may be active in one country, expired in another, or narrowed during prosecution. Regulatory approval alone does not establish patent protection.

When does Jylamvo lose exclusivity?

Jylamvo’s exclusivity position depends on jurisdiction and on whether enforceable formulation, packaging, or method-of-use patents remain active.

Exclusivity component	Jylamvo position
Methotrexate active ingredient	Long off-patent history
Oral-solution dosage form	Potential formulation protection, requiring patent-family verification
Pediatric use	Potential method-of-use protection, generally narrower than composition claims
U.S. FDA approval	Jylamvo is not established as an FDA-approved product in the cited sources
EU/UK regulatory status	Authorized and marketed as a methotrexate oral solution
Biosimilar exclusivity	Not applicable; methotrexate is a small molecule
Generic substitution risk	Depends on national authorization rules and formulation equivalence

In Europe, generic or hybrid applicants may enter after relevant data, market, and patent barriers expire or are successfully challenged. Because Jylamvo is a liquid formulation, a competing product may need to demonstrate pharmaceutical equivalence, acceptable stability, microbial quality, dose uniformity, and suitable excipient justification.

What is the Orange Book status of Jylamvo?

Jylamvo does not have an established Orange Book status in the cited FDA sources. The U.S. product with a similar commercial concept is Xatmep, a methotrexate oral solution marketed by Silvergate Pharmaceuticals. Xatmep is a separate product with its own FDA application, formulation, labeling, and potential patent records. [2][3]

The distinction matters commercially. A manufacturer seeking to enter the United States cannot rely on Jylamvo’s European authorization as a substitute for an FDA approval pathway. It would need to select an appropriate route, such as:

• an abbreviated new drug application, if the product qualifies as a generic equivalent;
• a 505(b)(2) application, if reliance on published literature or an approved reference product is appropriate; or
• a full new drug application, if formulation, clinical, or product differences require broader support.

Methotrexate is a high-risk medicine because inadvertent daily rather than weekly administration has caused serious and fatal medication errors. FDA labeling for oral methotrexate products emphasizes weekly dosing and dispensing controls. [2][3]

How does Jylamvo compare with Xatmep?

Jylamvo and Xatmep compete in the oral methotrexate solution segment but are not interchangeable regulatory products merely because both contain methotrexate.

Attribute	Jylamvo	Xatmep
Active ingredient	Methotrexate	Methotrexate
Dosage form	Oral solution	Oral solution
Strength	2 mg/mL	2.5 mg/mL
Primary market	Europe and other non-U.S. markets	United States
Key use cases	Rheumatology, dermatology, pediatric rheumatology, leukemia	FDA-labeled methotrexate indications
Taste system	Raspberry flavor and sucralose listed in product information	U.S. formulation and flavor system governed by FDA labeling
Regulatory basis	European authorization	FDA approval
Substitution	Depends on national rules	Depends on U.S. pharmacy and state requirements
Main differentiation	European liquid formulation and dosing presentation	U.S. regulatory status and market access

The concentration difference has practical significance. A 2 mg/mL product requires a larger volume for the same dose than a 2.5 mg/mL product. That can affect pediatric acceptability, caregiver burden, syringe selection, and the risk of volume-based dosing errors.

What excipient strategy could create commercial opportunities?

The strongest opportunities are not broad substitution of every excipient. They are targeted improvements that solve a defined clinical or operational problem.

Improve taste without increasing dose complexity

Methotrexate has an unpleasant taste. Sucralose and raspberry flavor provide a basic taste-masking approach, but pediatric acceptance can vary by age, disease, and prior treatment experience.

Potential commercial approaches include:

• a more effective flavor system;
• reduced aftertaste;
• flavor options selected for regional preferences;
• taste-masking through complexation or encapsulation;
• lower sweetener load; and
• a formulation compatible with small-volume administration.

A taste improvement could support adherence, but it would require human palatability testing and stability data. Taste claims alone are unlikely to support strong patent protection unless linked to a defined composition or measurable performance.

Reduce preservative-related constraints

Sodium benzoate is a practical preservative for a multidose liquid, but preservative systems can raise questions involving age restrictions, excipient exposure, and compatibility with container materials.

A competitor could investigate:

• alternative preservatives;
• preservative-free unit-dose packaging;
• lower preservative concentrations;
• aseptic manufacturing;
• improved closure systems; and
• smaller package sizes that reduce in-use exposure.

A preservative-free presentation could command a premium in pediatric or institutional channels, but it would increase manufacturing, packaging, and quality-control costs.

Develop a higher-concentration solution

A higher-concentration methotrexate solution could reduce administration volume. The opportunity is technically attractive for patients requiring larger weekly doses, but concentration changes can affect:

• solubility;
• precipitation;
• taste intensity;
• dose-measurement accuracy;
• accidental overdose severity;
• syringe compatibility; and
• stability after opening.

A higher-strength product may require a new regulatory application rather than a simple line extension. It could also face a more difficult medication-error assessment because small volume errors would produce larger dose deviations.

Improve container and dosing-device integration

The delivery system is a major commercial opportunity. Product improvements could include:

• a bottle designed for low residual volume;
• a calibrated oral syringe with a larger barrel;
• an adapter that reduces spillage;
• unit-dose packaging for institutions;
• a bottle cap with prominent weekly-use warnings;
• barcode-enabled dispensing support; and
• packaging that separates the product from daily medicines.

Device claims may provide a more defensible competitive position than routine excipient substitutions, especially when linked to dose accuracy or error reduction.

What manufacturing and intellectual-property barriers affect competitors?

A direct competitor must reproduce more than the qualitative ingredient list. It must achieve a stable, reproducible product with acceptable microbial quality and consistent delivery over the full shelf life.

Key manufacturing barriers include:

1. Methotrexate solubility and pH control.
2. Uniformity across the first and last doses in a multidose bottle.
3. Preservative efficacy after repeated opening.
4. Compatibility with high-density polyethylene, glass, elastomers, and oral syringes.
5. Control of degradation products.
6. Flavor and sweetener consistency.
7. Accurate fill volume and low residual product.
8. Stability after initial opening.
9. Transport performance across temperature excursions.
10. Safe handling of a cytotoxic active ingredient during manufacturing.

A patent strategy can combine composition claims with narrower fallback claims covering pH ranges, excipient ratios, container materials, stability thresholds, or dosing devices. Broad claims directed simply to "methotrexate oral solution" may face validity and prior-art pressure because oral methotrexate liquids predate Jylamvo.

Which companies are challenging Jylamvo?

No verified public Paragraph IV challenge, U.S. patent litigation, or Jylamvo-specific settlement agreement is established in the cited sources. Paragraph IV litigation is primarily relevant to an FDA-approved reference product with Orange Book-listed patents. Since Jylamvo is not established as an FDA reference product in the cited materials, European generic and hybrid applications are the more relevant competitive pathway.

Potential competitors include:

• manufacturers of generic methotrexate oral solutions;
• specialty pediatric pharmaceutical companies;
• U.S. developers using Xatmep as a reference product;
• hospital-compounding networks;
• manufacturers of unit-dose oral cytotoxic medicines; and
• specialty generics companies with liquid formulation capabilities.

The most credible competitive threat is a product with equivalent concentration, familiar flavor, validated oral-syringe dosing, and reliable supply. A formulation that is merely cheaper may not displace an established product if physicians and caregivers value the dosing system and regulatory history.

What regulatory status affects commercial expansion?

Jylamvo has European authorization for oral methotrexate use across several inflammatory and hematologic indications. The product’s regulatory value is tied to its established oral-solution presentation and risk-controlled weekly administration. [1]

Commercial expansion into new territories would require attention to:

• local approval pathways for generic, hybrid, or abridged products;
• excipient acceptability by age group;
• local labeling for weekly dosing;
• pharmacovigilance obligations;
• cytotoxic handling requirements;
• package leaflet readability;
• device calibration and dose units;
• pediatric investigation requirements; and
• local substitution rules.

A reformulated product that changes the concentration, flavor, preservative, or device may lose the regulatory simplicity of a formulation copy and move into a more complex variation or new-product pathway.

How strong is the Jylamvo patent estate?

The underlying methotrexate compound estate is weak because methotrexate has been marketed for decades. The potential strength of Jylamvo’s estate is therefore concentrated in narrower rights covering formulation, stability, packaging, dosing, and use.

Estate component	Relative strength
Methotrexate compound	Very weak or expired
General oral liquid	Weak unless narrowly defined
Specific excipient combination	Moderate if supported by unexpected stability or tolerability data
pH and buffer ranges	Moderate to weak, depending on prior art and claim breadth
Multidose container and syringe	Moderate where tied to measurable dose-control performance
Weekly dosing methods	Potentially useful but vulnerable to eligibility and scope limits
Manufacturing process	Moderate if process parameters produce a defined quality advantage
Brand and trade dress	Commercially relevant but separate from patent protection

The most durable strategy is likely a layered estate: formulation claims, stability claims, device claims, and trademark protection. No single excipient is likely to create a durable barrier by itself.

What revenue exposure and launch scenarios exist?

Jylamvo’s revenue exposure is concentrated in patients who need liquid administration rather than tablets or injections. The highest-value segments are likely pediatric rheumatology, pediatric oncology, patients with swallowing difficulty, and caregivers who require measured oral dosing.

Launch scenario	Market effect	Main risk
Same-strength generic liquid	Direct price competition	Limited differentiation
Lower-volume higher-strength liquid	Premium opportunity	Dose-error and stability risk
Better-tasting pediatric product	Adherence and caregiver benefit	Taste claims may be difficult to protect
Preservative-free unit dose	Institutional and pediatric niche	Higher packaging cost
Integrated syringe and warning system	Error-reduction positioning	Device and regulatory complexity
Regional flavor variants	Local commercial fit	Supply-chain complexity
Hospital-focused presentation	Institutional procurement access	Lower retail brand visibility

The most attractive opportunity is a product that combines a clinically familiar methotrexate concentration with a demonstrably better dosing system. Pure excipient substitution is more likely to generate incremental value than a major franchise displacement.

Key Takeaways

• Jylamvo is a 2 mg/mL methotrexate oral solution using macrogol 400, sucralose, sodium benzoate, citrate buffering, raspberry flavor, and purified water.
• Its commercial differentiation comes from liquid delivery, pediatric usability, taste masking, and weekly-dose safety controls.
• Methotrexate compound protection is no longer commercially meaningful. Any enforceable Jylamvo-related protection would likely focus on formulation, stability, packaging, device, or use.
• Jylamvo is not established as an FDA Orange Book reference product in the cited sources. Xatmep is the more relevant U.S. comparator.
• The strongest product opportunities are improved taste, reduced administration volume, preservative-free unit doses, and integrated dosing devices.
• The principal technical barriers are methotrexate stability, preservative efficacy, dose uniformity, container compatibility, and medication-error prevention.
• No verified public Paragraph IV challenge, Jylamvo-specific U.S. litigation, or settlement agreement is established in the cited sources.
• A layered formulation and device strategy is more commercially defensible than reliance on a single excipient claim.

Frequently Asked Questions

Is Jylamvo the same as Xatmep?

No. Both are methotrexate oral solutions, but they are separate products with different regulatory approvals, concentrations, markets, labeling, and formulation records. Jylamvo is 2 mg/mL, while Xatmep is 2.5 mg/mL.

Can a generic manufacturer copy Jylamvo’s excipients?

A manufacturer may be able to use the same excipients if no enforceable patent or regulatory restriction prevents it. It must still demonstrate suitable quality, stability, microbial control, dose uniformity, and regulatory equivalence in the target jurisdiction.

Why is weekly dosing important for Jylamvo?

Methotrexate is commonly administered once weekly for inflammatory diseases. Daily administration errors can cause severe toxicity or death, so the product label, bottle, syringe, and dispensing process must communicate weekly use clearly.

Could a higher-concentration Jylamvo product be commercially successful?

Yes, particularly for patients requiring larger doses, because it could reduce administration volume. The product would face greater requirements for stability, taste, dose accuracy, and medication-error control.

Are biosimilars a competitive threat to Jylamvo?

No. Methotrexate is a small-molecule drug, so the relevant competitors are generic, hybrid, reformulated, and compounded products rather than biosimilars.

References

1. European Medicines Agency. (2024). Jylamvo: EPAR product information. https://www.ema.europa.eu/en/medicines/human/EPAR/jylamvo
2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (2024). Xatmep prescribing information. Silvergate Pharmaceuticals. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208603s000lbl.pdf